Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 32402 | 139 | 24.2 | 37% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 6 | 4 | GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY | 1371034 |
| 109 | 3 | RECTAL CANCER//COLORECTAL CANCER//COLONOSCOPY | 71522 |
| 1176 | 2 | THYMIDYLATE SYNTHASE//THYMIDINE PHOSPHORYLASE//5 FLUOROURACIL | 9333 |
| 32402 | 1 | CARMOFUR//5 FLUOROURACIL AND 1 HEXYLCARBAMOYL 5 FLUOROURACIL//HCFU | 139 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | CARMOFUR | authKW | 499268 | 4% | 45% | 5 |
| 2 | 5 FLUOROURACIL AND 1 HEXYLCARBAMOYL 5 FLUOROURACIL | authKW | 439360 | 1% | 100% | 2 |
| 3 | HCFU | authKW | 439356 | 3% | 50% | 4 |
| 4 | 1 HEXYLCARBAMOYL 5 FLUOROURACIL | authKW | 390538 | 3% | 44% | 4 |
| 5 | ORAL ADJUVANT CHEMOTHERAPY | authKW | 292906 | 1% | 67% | 2 |
| 6 | 1 HEXYLEARBAMOYL 5 FLUOROURACIL | authKW | 219680 | 1% | 100% | 1 |
| 7 | 1 TETRAHYDRO 2 FURANYL 5 FLUOROURACIL | authKW | 219680 | 1% | 100% | 1 |
| 8 | ADJUVANT AND NEOADJUVANT METHODS | authKW | 219680 | 1% | 100% | 1 |
| 9 | ALLERGIC LIVER INJURY | authKW | 219680 | 1% | 100% | 1 |
| 10 | ANTIGEN EXPRESSED ALTERNATIVELY TO ALPHA FETOPROTEIN | authKW | 219680 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Oncology | 1528 | 54% | 0% | 75 |
| 2 | Pharmacology & Pharmacy | 307 | 29% | 0% | 40 |
| 3 | Chemistry, Medicinal | 29 | 5% | 0% | 7 |
| 4 | Gastroenterology & Hepatology | 28 | 5% | 0% | 7 |
| 5 | Surgery | 20 | 9% | 0% | 12 |
| 6 | Medicine, Research & Experimental | 6 | 4% | 0% | 5 |
| 7 | Chemistry, Multidisciplinary | 5 | 7% | 0% | 10 |
| 8 | Geriatrics & Gerontology | 1 | 1% | 0% | 1 |
| 9 | Pathology | 1 | 1% | 0% | 2 |
| 10 | Nursing | 1 | 1% | 0% | 1 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | J ANESE SOC CANC COLON RECTUM MED | 219680 | 1% | 100% | 1 |
| 2 | J ANESE SOC STRATEGIES CANC THER Y | 219680 | 1% | 100% | 1 |
| 3 | META ANAL PROJECTSECRETARIATSAKYO KU | 219680 | 1% | 100% | 1 |
| 4 | SURG TEACHING HOSP 2 | 219680 | 1% | 100% | 1 |
| 5 | GENET MONITORING | 54919 | 1% | 25% | 1 |
| 6 | PATHOL SCI TECHNOL | 35145 | 1% | 8% | 2 |
| 7 | LOWER GI | 31381 | 1% | 14% | 1 |
| 8 | GF GAUZE NEW ANTIBIOT | 27458 | 1% | 13% | 1 |
| 9 | AN SYSIN HUMAN ECOL ENVIRONM HYG | 18305 | 1% | 8% | 1 |
| 10 | CATALYSIS PLICAT | 18305 | 1% | 8% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY | 12203 | 1% | 6% | 1 |
| 2 | CHEMOTHERAPY-TOKYO | 10567 | 2% | 2% | 3 |
| 3 | EKSPERIMENTALNAYA ONKOLOGIYA | 6387 | 4% | 0% | 6 |
| 4 | CANCER TREATMENT REPORTS | 4879 | 5% | 0% | 7 |
| 5 | GANN | 2644 | 2% | 0% | 3 |
| 6 | ONKOLOGIE | 1352 | 3% | 0% | 4 |
| 7 | CANCER INVESTIGATION | 1257 | 3% | 0% | 4 |
| 8 | JOURNAL OF PHARMACOBIO-DYNAMICS | 1209 | 2% | 0% | 3 |
| 9 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1046 | 2% | 0% | 3 |
| 10 | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH | 914 | 1% | 0% | 2 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | MAEHARA, Y , SUGIMACHI, K , OGAWA, M , KAKEGAWA, T , TOMITA, M , AKIYOSHI, S , (1998) POSTOPERATIVE ADJUVANT CHEMOTHERAPY WITH 1-HEXYLCARBAMOYL-5-FLUOROURACIL IN PATIENTS WITH COLORECTAL CANCER AND AT A HIGH RISK FOR RECURRENCE.ANTICANCER RESEARCH. VOL. 18. ISSUE 6B. P. 4629 -4634 | 11 | 61% | 5 |
| 2 | PALMERI, S , GEBBIA, V , RUSSO, A , ARMATA, MG , GEBBIA, N , RAUSA, L , (1990) ORAL TEGAFUR IN THE TREATMENT OF GASTROINTESTINAL-TRACT CANCERS - A PHASE-II STUDY.BRITISH JOURNAL OF CANCER. VOL. 61. ISSUE 3. P. 475-478 | 9 | 100% | 22 |
| 3 | SAKAMOTO, J , HAMADA, C , RAHMAN, M , KODAIRA, S , ITO, K , NAKAZATO, H , OHASHI, Y , YASUTOMI, M , (2005) AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF ADJUVANT THERAPY WITH CARMOFUR IN PATIENTS WITH CURATIVELY RESECTED COLON CANCER.JAPANESE JOURNAL OF CLINICAL ONCOLOGY. VOL. 35. ISSUE 9. P. 536-544 | 11 | 42% | 3 |
| 4 | SUOU, T , TANAKA, K , OKANO, J , SHIOTA, G , HORIE, Y , HORIE, Y , KAWASAKI, H , (2002) A CASE WITH HEPATIC FIBROSIS SHOWING ASCITES AND ESOPHAGEAL VARICES INDUCED BY ORAL UFTR ADMINISTRATION.HEPATOLOGY RESEARCH. VOL. 22. ISSUE 2. P. 161-165 | 6 | 75% | 0 |
| 5 | SAKAMOTO, J , KODAIRA, S , HAMADA, C , ITO, K , MAEHARA, Y , TAKAGI, H , SUGIMACHI, K , NAKAZATO, H , (2001) AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF LONG SUPPORTED ADJUVANT CHEMOTHERAPY WITH ORAL CARMOFUR IN PATIENTS WITH CURATIVELY RESECTED COLORECTAL CANCER.ONCOLOGY REPORTS. VOL. 8. ISSUE 3. P. 697 -703 | 7 | 58% | 9 |
| 6 | IWAGAKI, H , TANAKA, N , ESATO, K , KAIBARA, N , SANO, K , DOHI, K , TOGE, T , NAKAMURA, T , NAKASATO, H , ORITA, K , (2001) POST-OPERATIVE ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER WITH 5-FLUOROURACIL (5-FU) INFUSION COMBINED WITH 1-HEXYLCARBAMOYL-5-FLUOROURACIL (HCFU) ORAL ADMINISTRATION AFTER CURATIVE RESECTION.ANTICANCER RESEARCH. VOL. 21. ISSUE 6A. P. 4163 -4168 | 7 | 58% | 2 |
| 7 | IWAGAKI, H , TANAKA, N , ESATO, K , KAIBARA, N , SANO, K , DOHI, K , NAKAMURA, T , NAKASATO, H , ORITA, K , (2000) RANDOMIZED CONTROLLED TRIAL OF 5-FLUOROURACIL (5-FU) INFUSION COMBINED WITH 1-HEXYLCARBAMOYL-5-FLUOROURACIL (HCFU) ORAL ADMINISTRATION AND HCFU ALONE AS POSTOPERATIVE ADJUVANT CHEMOTHERAPY FOR COLORECTAL CANCER.ANTICANCER RESEARCH. VOL. 20. ISSUE 5C. P. 3727 -3734 | 9 | 43% | 3 |
| 8 | KAWABATA, N , YANO, K , OHNO, H , NAKASHIMA, T , (1991) EFFECT OF L-CYSTEINE ON PLASMA-CONCENTRATION AND URINARY-EXCRETION OF 1-(TETRAHYDRO-2-FURANYL)-5-FLUOROURACIL METABOLITES.CHEMICAL & PHARMACEUTICAL BULLETIN. VOL. 39. ISSUE 4. P. 1068 -1071 | 7 | 78% | 0 |
| 9 | SUGIMACHI, K , MAEHARA, Y , OGAWA, M , KAKEGAWA, T , TOMITA, M , AKIYOSHI, T , (1996) POSTOPERATIVE CHEMOTHERAPY FOR COLORECTAL CANCER BY COMBINING 5-FLUOROURACIL INFUSION AND 1-HEXYLCARBAMOYL-5-FLUOROURACIL ADMINISTRATION AFTER CURATIVE RESECTION.CANCER. VOL. 77. ISSUE 1. P. 36-43 | 8 | 38% | 14 |
| 10 | HADFIELD, AF , SARTORELLI, AC , (1984) THE PHARMACOLOGY OF PRODRUGS OF 5-FLUOROURACIL AND 1-BETA-D-ARABINOFURANOSYLCYTOSINE.ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY. VOL. 20. ISSUE . P. 21-67 | 13 | 41% | 30 |
Classes with closest relation at Level 1 |